UK markets closed

Silence Therapeutics plc (SLN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
11.88-0.11 (-0.92%)
At close: 04:00PM EDT
11.99 +0.11 (+0.93%)
After hours: 04:17PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close11.99
Open11.64
Bid4.91 x 1200
Ask19.15 x 900
Day's range10.48 - 13.00
52-week range7.80 - 28.35
Volume62,291
Avg. volume21,404
Market cap355.573M
Beta (5Y monthly)1.38
PE ratio (TTM)N/A
EPS (TTM)-1.58
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est4,379.47
  • Business Wire

    Silence Therapeutics to Present at Jefferies Healthcare Conference

    LONDON, June 02, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will present at the Jefferies Healthcare Conference on Thursday, June 9th at 10:00 a.m. EDT / 2:00 p.m. GMT.

  • Business Wire

    Silence Therapeutics to Participate in Fireside Chat at H.C. Wainwright Global Investment Conference

    LONDON, May 18, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that the Company will participate in a virtual fireside chat during the H.C. Wainwright Global Investment Conference, on May 23-26, 2022.

  • Business Wire

    Silence Therapeutics Reports First Quarter 2022 Results

    LONDON, May 16, 2022--Silence Therapeutics plc, Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today reported its financial results for the first quarter ended March 31, 2022 and reviewed recent business highlights.